click below
click below
Normal Size Small Size show me how
HIV Pharm
Name | Class | MOA | Side Effects | Notes |
---|---|---|---|---|
Maraviroc | CCR5 Antagonist | |||
Enfuvirtide | Fusion Inhibitor | |||
Fuzeon | Fusion Inhibitor | |||
Lamivudine (3TC) | NRTI | |||
Emtricitibine (FTC) | NRTI | |||
Abacavir | NRTI | - must screen for HLA-B*5701 - only NRTI without Hep B activity | ||
Tenofivir Disoproxol Fumarate (TDF) | NRTI | - Fanconi's Syndrome: renal tubular dysfunction, phosphaturia, and glucosuria - headache - nausea - vomiting - diarrhea - rare lactic acidosis - bone demineralization | ||
Tenofivir Alafenamide (TAF) | NRTI | - less nephrotoxic - raises LDL cholesterol - weight gain | ||
Efavirenz | NNRTI | - crosses BBB - nightmares/vivid dreams that lessen over time - K103N Mutation confers resistance to three drugs in class | - Atripla: Efavirenz, Emtricitaine, and Tenofovir | |
Rilpivirine | NNRTI | - Complera: Truvada + Rilpivirine | ||
Atazanavir | Protease Inhibitor | - Insulin Resistance - Hyperglycemia - Diabetes - Dyslipidemia (increases HDL) - Asymptomatic hyperbilirubinemia (indirect bili) - Fat Redistribution - Accumulative Exposure increased risk of myocardial infarction - PR longation - nephrolithiasis | ||
Darunavir | Protease Inhibitor | - blocks cellular proteases - CYP450 interactions - Insulin Resistance - Hyperglycemia - Diabetes - Dyslipidemia - Fat Redistribution - Accumulative Exposure increased risk of myocardial infarction | ||
Indinavir | Protease Inhibitor | - kidney effects - nephrolithiasis to sterile pyuria: drug deposits, need to drink 2-3 L H2O/day, must take on empty stomach | ||
Raltegravir | Integrase Inhibitor | - targets HIV-1 integrase - backbone agent in ART - disadvantage is bid dosing | ||
Dolutegravir | Integrase Inhibitor | - different resistance pattern than Raltegravir - Triumeq: Dolutegravir + 3TC/Abacavir may be superior to Atripla | ||
Elvitegravir | Integrase Inhibitor | - found in quad pill - combine with Cobicistat to allow for 1/day dosing | ||
Bictegravir | Integrase Inhibitor | |||
Ritonavir | Pharmacokinetic (PK) Booster | - pharmokinetic booster - RTV Boost: blocks clearance of second protease inhibitor | ||
Cobicistat | Pharmacokinetic (PK) Booster | - no activity against HIV - potent CP3A inhibitor - pharmocokinetic enhancer of Elvitegravir: allows for 1/day dosing |